Colin Freund takes new CEO job at Modra Pharma; Compass recruits Pfizer, Biogen vets to C-suite
→ Amsterdam-based Modra Pharmaceuticals has tapped a permanent CEO to guide its pipeline of oral chemotherapies as it wraps up a Phase Ib/IIa study for the lead program — a tablet formulation of docetaxel. Colin Freund comes with fresh CEO experience at Que Oncology as well as a previous stints at Trangene and GPC Biotech. Eric van der Putten, the Aglaia Biomedical Ventures partner who was filling the role ad interim, will recede to a board director role. Meanwhile Edwin De Wit has also joined the company as head of oncology development.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters